| |

Vaccines
Even better than curing a disease is never having the disease at all.
Vaccines are the key to preventing the world’s deadliest diseases. SBRI is
taking a leading role in development of new vaccines for malaria and HIV/AIDS
Malaria Program
Led by Patrick Duffy, M.D.,
along with Michal Fried, Ph.D.,
Malcolm Gardner, Ph.D.,
Stefan Kappe, Ph.D., Joe Smith,
Ph.D., and Ruobing Wang, M.D., Ph.D., SBRI’s Malaria
(MAD) Program combines vaccine candidate discovery with clinical field studies
in Tanzania to develop viable malaria vaccines. Studies are focused on pregnancy
malaria, malaria in children and liver stage malaria.
Considerable progress has already been made in identifying antigens --
proteins that stimulate the immune system -- that may be part of an effective
vaccine against malaria in pregnant women. A similar strategy is being applied
to develop a vaccine against a form of malaria that strikes children. SBRI
scientists have also demonstrated in a laboratory model that a genetically
attenuated whole-organism malaria vaccine that prevents infection is possible.
Viral Vaccines Program
The Viral Vaccines Program, headed by Leo Stamatatos,
Ph.D., with Helen Horton, Ph.D., and
Don Sodora, Ph.D., targets the discovery of
protein-based vaccines that elicit broad-based protection against many HIV
variants and conducts experimental testing as a basis for clinical trials for an
HIV/AIDS vaccine. The focus of the program is to create vaccines that elicit
long-lasting immunity and protect against different strains of HIV, anywhere in
the world. Researchers at SBRI are seeking “smart” vaccines delivering a
“one-two punch” to block infection as the first line of defense and to kill
infected cells if the virus slips by. Our researchers are the first to
demonstrate that treatment with high levels of antibodies, immediately post-HIV
infection, significantly prolongs life.
|
|